Advances in Design and Development of Sodium Channel Blockers

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  Robert G. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2012, The Cochrane database of systematic reviews.

[3]  Yang Wang,et al.  Genetic polymorphisms in the SCN8A gene are associated with suicidal behavior in psychiatric disorders in the Chinese population , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[4]  R. Pang,et al.  TNF-α contributes to up-regulation of Nav1.3 and Nav1.8 in DRG neurons following motor fiber injury , 2010, PAIN®.

[5]  M. Hanna,et al.  Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. , 2010, Current opinion in neurology.

[6]  M. Gurevitz,et al.  Coupling between residues on S4 and S1 defines the voltage-sensor resting conformation in NaChBac. , 2010, Biophysical journal.

[7]  M. Finnin,et al.  Vernakalant: A novel agent for the termination of atrial fibrillation. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  C. Bezzina,et al.  Sodium channel (dys)function and cardiac arrhythmias. , 2010, Cardiovascular therapeutics.

[9]  S. Dib-Hajj,et al.  Sodium channels in normal and pathological pain. , 2010, Annual review of neuroscience.

[10]  W. Catterall,et al.  NaV1.1 channels and epilepsy , 2010, The Journal of physiology.

[11]  R. Cregg,et al.  Pain channelopathies , 2010, The Journal of physiology.

[12]  Massimo Mantegazza,et al.  Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders , 2010, The Lancet Neurology.

[13]  Cenk Ayata,et al.  Cortical Spreading Depression and Migraine , 2010, Current neurology and neuroscience reports.

[14]  A. Lampert,et al.  Sodium channelopathies and pain , 2010, Pflügers Archiv - European Journal of Physiology.

[15]  W. Catterall,et al.  Sequential formation of ion pairs during activation of a sodium channel voltage sensor , 2009, Proceedings of the National Academy of Sciences.

[16]  M. Djamgoz,et al.  Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer. , 2009, European journal of pharmacology.

[17]  M. D. de Groot,et al.  Subtype‐selective targeting of voltage‐gated sodium channels , 2009, British journal of pharmacology.

[18]  D. Riva,et al.  Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes , 2009, American journal of medical genetics. Part A.

[19]  R. Griggs,et al.  Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias , 2009, Current opinion in neurology.

[20]  M. Kiernan,et al.  Upregulation of persistent sodium conductances in familial ALS , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  Monique Bernard,et al.  3-(R)-[3-(2-Methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine Bromhydrate (F 15845) Prevents Ischemia-Induced Heart Remodeling by Reduction of the Intracellular Na+ Overload , 2009, Journal of Pharmacology and Experimental Therapeutics.

[22]  M. Bellis,et al.  G.P.14.11 Newly synthesized mexiletine and tocainide analogues are potent use-dependent blockers of skeletal muscle sodium channels: Potential implication for the antimyotonic activity , 2009, Neuromuscular Disorders.

[23]  M. Leppert,et al.  A Role of SCN9A in Human Epilepsies, As a Cause of Febrile Seizures and As a Potential Modifier of Dravet Syndrome , 2009, PLoS genetics.

[24]  N. Nukina,et al.  A Functional Null Mutation of SCN1B in a Patient with Dravet Syndrome , 2009, The Journal of Neuroscience.

[25]  S. Waxman,et al.  Sodium channel activity modulates multiple functions in microglia , 2009, Glia.

[26]  A. L. Goldin,et al.  A BAC transgenic mouse model reveals neuron subtype-specific effects of a Generalized Epilepsy with Febrile Seizures Plus (GEFS+) mutation , 2009, Neurobiology of Disease.

[27]  S. Mellgren,et al.  Two novel SCN9A mutations causing insensitivity to pain , 2009, Pain.

[28]  M. Kiernan.  Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis , 2009, Experimental Neurology.

[29]  B. Fontaine,et al.  Cold‐induced disruption of Na+ channel slow inactivation underlies paralysis in highly thermosensitive paramyotonia , 2009, The Journal of physiology.

[30]  Ludovic C. Gillet,et al.  Voltage-gated Sodium Channel Activity Promotes Cysteine Cathepsin-dependent Invasiveness and Colony Growth of Human Cancer Cells* , 2009, Journal of Biological Chemistry.

[31]  M. Ferrari,et al.  First Mutation in the Voltage-Gated Nav1.1 Subunit Gene SCN1A with Co-Occurring Familial Hemiplegic Migraine and Epilepsy , 2009, Cephalalgia : an international journal of headache.

[32]  M. Patel,et al.  Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential. , 2009, Current topics in medicinal chemistry.

[33]  N. Mercuri,et al.  Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis , 2009, Experimental Neurology.

[34]  B. Vacher,et al.  F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models , 2009, British journal of pharmacology.

[35]  J. Burgunder,et al.  A novel dominant mutation of the Nav1.4 α-subunit domain I leading to sodium channel myotonia , 2008, Neurology.

[36]  A. De Luca,et al.  Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents. , 2008, European journal of medicinal chemistry.

[37]  Kristopher M. Kahlig,et al.  Impaired NaV1.2 function and reduced cell surface expression in benign familial neonatal‐infantile seizures , 2008, Epilepsia.

[38]  M. Ferrari,et al.  Divergent sodium channel defects in familial hemiplegic migraine , 2008, Proceedings of the National Academy of Sciences.

[39]  B. Vacher,et al.  Sodium late current blockers in ischemia reperfusion: is the bullet magic? , 2008, Journal of medicinal chemistry.

[40]  R. Shank,et al.  Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate , 2008, CNS neuroscience & therapeutics.

[41]  D. Ragsdale.  How do mutant Nav1.1 sodium channels cause epilepsy? , 2008, Brain Research Reviews.

[42]  J. Camm,et al.  Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[43]  M. Meisler,et al.  Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy , 2008, Neuroscience Letters.

[44]  S. Cannon,et al.  Cold-induced defects of sodium channel gating in atypical periodic paralysis plus myotonia , 2008, Neurology.

[45]  D. Saint.  The cardiac persistent sodium current: an appealing therapeutic target? , 2008, British journal of pharmacology.

[46]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[47]  M. Jarvis,et al.  A Selective Nav1.8 Sodium Channel Blocker, A-803467 [5-(4-Chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], Attenuates Spinal Neuronal Activity in Neuropathic Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[48]  I. Stamenkovic,et al.  Metastatic cancer cell. , 2008, Annual review of pathology.

[49]  S. Waxman.  Mechanisms of Disease: sodium channels and neuroprotection in multiple sclerosis—current status , 2008, Nature Clinical Practice Neurology.

[50]  W. Dodson,et al.  Definitions and Classification of Epilepsy , 2008 .

[51]  G. Lees,et al.  The Investigational Anticonvulsant Lacosamide Selectively Enhances Slow Inactivation of Voltage-Gated Sodium Channels , 2008, Molecular Pharmacology.

[52]  J. Farrar,et al.  Pharmacologic management of neuropathic pain: Evidence-based recommendations , 2007, PAIN.

[53]  J. Gargus,et al.  Novel mutation confirms seizure locus SCN1A is also familial hemiplegic migraine locus FHM3. , 2007, Pediatric neurology.

[54]  Sulayman D. Dib-Hajj,et al.  From genes to pain: Nav1.7 and human pain disorders , 2007, Trends in Neurosciences.

[55]  I. Scheffer,et al.  Generalized epilepsy with febrile seizures plus–associated sodium channel β1 subunit mutations severely reduce beta subunit–mediated modulation of sodium channel function , 2007, Neuroscience.

[56]  Kedar S Vaidya,et al.  Metastasis Suppressors and Their Roles in Breast Carcinoma , 2007, Journal of Mammary Gland Biology and Neoplasia.

[57]  E. Jakobsson,et al.  Sodium Channel Auxiliary Subunits , 2007, Journal of Molecular Microbiology and Biotechnology.

[58]  Matthew S. Johnson,et al.  A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat , 2007, Proceedings of the National Academy of Sciences.

[59]  F. Lehmann-Horn,et al.  Genotype-Phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis , 2007, Neurotherapeutics.

[60]  M. Dubé,et al.  Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations , 2007, Clinical genetics.

[61]  P. Calabresi,et al.  Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. , 2007, Trends in pharmacological sciences.

[62]  F. Walker.  Huntington's disease , 2007, The Lancet.

[63]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[64]  John N. Wood,et al.  SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes , 2006, Neuron.

[65]  R. Kloner,et al.  Ranolazine, an Inhibitor of the Late Sodium Channel Current, Reduces Postischemic Myocardial Dysfunction in the Rabbit , 2006, Journal of cardiovascular pharmacology and therapeutics.

[66]  D. Bechtold,et al.  Axonal protection achieved in a model of multiple sclerosis using lamotrigine , 2006, Journal of Neurology.

[67]  R. Sikes,et al.  Voltage-sensitive ion channels and cancer , 2006, Cancer and Metastasis Reviews.

[68]  R. Maj,et al.  Safinamide , 2006, Neurology.

[69]  L. Vacca,et al.  Symptom relief in Parkinson disease by safinamide , 2006, Neurology.

[70]  G. Avanzini,et al.  Effects in Neocortical Neurons of Mutations of the Nav1.2 Na+ Channel causing Benign Familial Neonatal-Infantile Seizures , 2006, The Journal of Neuroscience.

[71]  J. Le Guennec,et al.  Voltage-gated sodium channels: new targets in cancer therapy? , 2006, Current pharmaceutical design.

[72]  Massimo Mantegazza,et al.  Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy , 2006, Nature Neuroscience.

[73]  Y. Bersudsky.  Phenytoin: an anti-bipolar anticonvulsant? , 2006, The international journal of neuropsychopharmacology.

[74]  F. Colpaert,et al.  KC 12291: an atypical sodium channel blocker with myocardial antiischemic properties. , 2006, Cardiovascular drug reviews.

[75]  D. Fedida,et al.  RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. , 2006, Cardiovascular research.

[76]  G. Lees,et al.  Seeking a mechanism of action for the novel anticonvulsant lacosamide , 2006, Neuropharmacology.

[77]  R. Kapoor.  Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design , 2006, Current opinion in neurology.

[78]  S. Waxman,et al.  Fire and phantoms after spinal cord injury: Na+ channels and central pain , 2006, Trends in Neurosciences.

[79]  Frances M. Ashcroft,et al.  From molecule to malady , 2006, Nature.

[80]  J. Shryock,et al.  The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction , 2006 .

[81]  S. Vogel,et al.  Na+ channel pharmacology and molecular mechanisms of gating. , 2006, Current pharmaceutical design.

[82]  G. Drost,et al.  Drug treatment for myotonia. , 2006, The Cochrane database of systematic reviews.

[83]  A. Rice,et al.  New treatments for neuropathic pain. , 2006, Annual review of medicine.

[84]  William A. Catterall,et al.  International Union of Pharmacology. XLVII. Nomenclature and Structure-Function Relationships of Voltage-Gated Sodium Channels , 2005, Pharmacological Reviews.

[85]  Clifford J. Woolf,et al.  Upregulation of the Voltage-Gated Sodium Channel β2 Subunit in Neuropathic Pain Models: Characterization of Expression in Injured and Non-Injured Primary Sensory Neurons , 2005, The Journal of Neuroscience.

[86]  M. Seckl,et al.  Neuronal characteristics of small-cell lung cancer , 2005, British Journal of Cancer.

[87]  M. Meisler,et al.  Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation , 2005, Journal of Medical Genetics.

[88]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[89]  M. Meisler,et al.  Sodium channel mutations in epilepsy and other neurological disorders. , 2005, Journal of Clinical Investigation.

[90]  R. Coombes,et al.  Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis , 2005, Clinical Cancer Research.

[91]  Alfred L George,et al.  Inherited disorders of voltage-gated sodium channels. , 2005, The Journal of clinical investigation.

[92]  T. Strom,et al.  Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine , 2005, The Lancet.

[93]  E. Eisenberg,et al.  Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. , 2005, JAMA.

[94]  B. de Strooper,et al.  β Subunits of Voltage-gated Sodium Channels Are Novel Substrates of β-Site Amyloid Precursor Protein-cleaving Enzyme (BACE1) and γ-Secretase* , 2005, Journal of Biological Chemistry.

[95]  Peter K. Stys,et al.  General mechanisms of axonal damage and its prevention , 2005, Journal of the Neurological Sciences.

[96]  F. Lang,et al.  Ion Channels in Cell Proliferation and Apoptotic Cell Death , 2005, The Journal of Membrane Biology.

[97]  R. Schönherr.  Clinical Relevance of Ion Channels for Diagnosis and Therapy of Cancer , 2005, The Journal of Membrane Biology.

[98]  M. Filippi,et al.  Clinical trials in multiple sclerosis: methodological issues , 2005, Current opinion in neurology.

[99]  C. Valdivia,et al.  Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. , 2005, Journal of molecular and cellular cardiology.

[100]  R. Harden.  Chronic Neuropathic Pain: Mechanisms, Diagnosis, and Treatment , 2005 .

[101]  A. Lo,et al.  Sodium channels contribute to microglia/macrophage activation and function in EAE and MS , 2005, Glia.

[102]  A. Waldo,et al.  Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. , 2004, Journal of cardiovascular electrophysiology.

[103]  I. Leppik.  Zonisamide: chemistry, mechanism of action, and pharmacokinetics , 2004, Seizure.

[104]  Sulayman D. Dib-Hajj,et al.  Electrophysiological Properties of Mutant Nav1.7 Sodium Channels in a Painful Inherited Neuropathy , 2004, The Journal of Neuroscience.

[105]  P. Raskin,et al.  Topiramate vs placebo in painful diabetic neuropathy , 2004, Neurology.

[106]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[107]  J. Shryock,et al.  Antagonism by Ranolazine of the Pro-Arrhythmic Effects of Increasing Late INa in Guinea Pig Ventricular Myocytes , 2004, Journal of cardiovascular pharmacology.

[108]  Carlos G Vanoye,et al.  Noninactivating voltage-gated sodium channels in severe myoclonic epilepsy of infancy. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[109]  P. Facer,et al.  Expression of the sodium channel &bgr;3 subunit in injured human sensory neurons , 2004, Neuroreport.

[110]  R. Post.  Differing psychotropic profiles of the anticonvulsants in bipolar and other psychiatric disorders , 2004, Clinical Neuroscience Research.

[111]  Wolfgang Löscher,et al.  The neurobiology of antiepileptic drugs , 2004, Nature Reviews Neuroscience.

[112]  G. Perugi,et al.  Antiepileptic drugs: indications other than epilepsy. , 2004, Epileptic disorders : international epilepsy journal with videotape.

[113]  T. Ketter,et al.  A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. , 2004, The Journal of clinical psychiatry.

[114]  B. Chaitman,et al.  Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. , 2004, Journal of the American College of Cardiology.

[115]  C. Woolf.  Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. , 2004, Life sciences.

[116]  B. Ding,et al.  Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.

[117]  R. Hughes,et al.  The risk of cancer from azathioprine as a treatment for multiple sclerosis , 2004, European journal of neurology.

[118]  A. George,et al.  Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state‐dependent block , 2004, The Journal of physiology.

[119]  R. Sikes,et al.  Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. , 2003, Clinical prostate cancer.

[120]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[121]  R. Sikes,et al.  Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3. , 2003, Molecular cancer therapeutics.

[122]  A. De Luca,et al.  Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels. , 2003, Journal of medicinal chemistry.

[123]  A. De Luca,et al.  Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds. , 2003, Molecular pharmacology.

[124]  J. Calabrese,et al.  A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. , 2003, The Journal of clinical psychiatry.

[125]  M. Rogawski,et al.  Selective Antagonism of GluR5 Kainate-Receptor-Mediated Synaptic Currents by Topiramate in Rat Basolateral Amygdala Neurons , 2003, The Journal of Neuroscience.

[126]  J. Noebels,et al.  Topiramate alters excitatory synaptic transmission in mouse hippocampus , 2003, Epilepsy Research.

[127]  A. L. Goldin.  Mechanisms of sodium channel inactivation , 2003, Current Opinion in Neurobiology.

[128]  M. Szatkowski,et al.  Contribution of functional voltage‐gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: II. Secretory membrane activity , 2003, Journal of cellular physiology.

[129]  G. Strichartz,et al.  Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions , 2003, PAIN®.

[130]  P. Gerner,et al.  Tricyclic antidepressants as long-acting local anesthetics , 2003, PAIN®.

[131]  Josemir W Sander.  The epidemiology of epilepsy revisited , 2003, Current opinion in neurology.

[132]  E. García-Poblete,et al.  Sympathetic sprouting in dorsal root ganglia (DRG): a recent histological finding? , 2003, Histology and histopathology.

[133]  Yukitoshi Takahashi,et al.  Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. , 2003, Brain : a journal of neurology.

[134]  R. Maj,et al.  Anti-allodynic effect of NW-1029, a novel Na+ channel blocker, in experimental animal models of inflammatory and neuropathic pain , 2003, Pain.

[135]  J. Libiger,et al.  Antiepileptic drugs in schizophrenia: a review , 2002, European Psychiatry.

[136]  O. Devinsky,et al.  Psychiatric uses of antiepileptic treatments , 2002, Epilepsy & Behavior.

[137]  Vladimir Yarov-Yarovoy,et al.  Role of Amino Acid Residues in Transmembrane Segments IS6 and IIS6 of the Na+ Channel α Subunit in Voltage-dependent Gating and Drug Block* , 2002, The Journal of Biological Chemistry.

[138]  A. Coulombe,et al.  Anti-ischemic Compound KC 12291 Prevents Diastolic Contracture in Isolated Atria by Blockade of Voltage-Gated Sodium Channels , 2002, Journal of cardiovascular pharmacology.

[139]  M. Avoli,et al.  Neocortical Potassium Currents Are Enhanced by the Antiepileptic Drug Lamotrigine , 2002, Epilepsia.

[140]  M. Tominaga.  Molecular Mechanism of Nociception , 2002 .

[141]  H. Lerche,et al.  Enhanced inactivation and pH sensitivity of Na(+) channel mutations causing hypokalaemic periodic paralysis type II. , 2002, Brain : a journal of neurology.

[142]  S. Lawson.  Phenotype and Function of Somatic Primary Afferent Nociceptive Neurones with C‐, Aδ‐ or Aα/β‐Fibres , 2002, Experimental physiology.

[143]  Patrício Soares-da-Silva,et al.  Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024 , 2002, Neurochemical Research.

[144]  Andrew K. Dunn,et al.  Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model , 2002, Nature Medicine.

[145]  P. Hansson.  Neuropathic pain: clinical characteristics and diagnostic workup , 2002, European journal of pain.

[146]  W. Catterall,et al.  Role of the C-terminal domain in inactivation of brain and cardiac sodium channels , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[147]  A. De Luca,et al.  Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use‐dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo , 2001, British journal of pharmacology.

[148]  G. Bock,et al.  Sodium channels and neuronal hyperexcitability , 2001 .

[149]  T. Jensen,et al.  The clinical picture of neuropathic pain. , 2001, European journal of pharmacology.

[150]  M. Zimmermann,et al.  Pathobiology of neuropathic pain. , 2001, European journal of pharmacology.

[151]  C. Stucky,et al.  Mechanisms of pain , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[152]  A. Basbaum,et al.  Molecular mechanisms of nociception , 2001, Nature.

[153]  W. Lederer,et al.  Role of Sodium Channel Deglycosylation in the Genesis of Cardiac Arrhythmias in Heart Failure* , 2001, The Journal of Biological Chemistry.

[154]  B. Hille,et al.  Ionic channels of excitable membranes , 2001 .

[155]  C. Normann,et al.  Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. , 2001, The Journal of clinical psychiatry.

[156]  J. Balser,et al.  The cardiac sodium channel: gating function and molecular pharmacology. , 2001, Journal of molecular and cellular cardiology.

[157]  L. Seeberger,et al.  A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease , 2001, Neurology.

[158]  T. Jensen,et al.  Lamotrigine for central poststroke pain , 2001, Neurology.

[159]  J Brown,et al.  Molecular Determinants of Voltage-dependent Gating and Binding of Pore-blocking Drugs in Transmembrane Segment IIIS6 of the Na+ Channel α Subunit* , 2001, The Journal of Biological Chemistry.

[160]  A. De Luca,et al.  Synthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective blockers of voltage-gated Na(+) channels with increased potency and improved use-dependent activity. , 2000, Journal of medicinal chemistry.

[161]  B. Kerem,et al.  Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. , 2000, Circulation.

[162]  D. Simpson,et al.  A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy , 2000, Neurology.

[163]  A. Rush,et al.  Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[164]  W. Catterall,et al.  From Ionic Currents to Molecular Mechanisms The Structure and Function of Voltage-Gated Sodium Channels , 2000, Neuron.

[165]  S. Shorvon.  Oxcarbazepine: a review , 2000, Seizure.

[166]  P. Kwan,et al.  Early identification of refractory epilepsy. , 2000, The New England journal of medicine.

[167]  C. Woolf,et al.  Neuropathic pain: aetiology, symptoms, mechanisms, and management , 1999, The Lancet.

[168]  M L Brown,et al.  Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. , 1999, Journal of medicinal chemistry.

[169]  J. Calabrese,et al.  A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. , 1999, The Journal of clinical psychiatry.

[170]  Ichiro Kanazawa,et al.  Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine , 1999, Journal of the Neurological Sciences.

[171]  B. Herweg,et al.  Oral Antiarrhythmic Drugs Used for Arrhythmia Prevention , 1998 .

[172]  L. Vernich,et al.  Nortriptyline versus amitriptyline in postherpetic neuralgia , 1998, Neurology.

[173]  Samuel F. Berkovic,et al.  Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel ß1 subunit gene SCN1B , 1998, Nature Genetics.

[174]  D. Rampe,et al.  The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. , 1998, The Journal of pharmacology and experimental therapeutics.

[175]  P. Raskin,et al.  Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy , 1998, Neurology.

[176]  Douglas C. Wallace,et al.  Radicals r'aging , 1998, Nature Genetics.

[177]  A. George,et al.  A novel muscle sodium channel mutation causes painful congenital myotonia , 1997, Annals of neurology.

[178]  T Narahashi,et al.  Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. , 1997, The Journal of pharmacology and experimental therapeutics.

[179]  P. Abel,et al.  Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. , 1997, The American journal of pathology.

[180]  P. Barnéoud,et al.  Neuroprotective effects of riluzole on a model of parkinson's disease in the rat , 1996, Neuroscience.

[181]  G Bernardi,et al.  Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. , 1996, European journal of pharmacology.

[182]  M. Mcdermott,et al.  A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[183]  G. R. Arthur,et al.  The Analgesic Response to Intravenous Lidocaine in the Treatment of Neuropathic Pain , 1996, Anesthesia and analgesia.

[184]  S L Shafer,et al.  Prolonged Alleviation of Tactile Allodynia by Intravenous Lidocaine in Neuropathic Rats , 1995, Anesthesiology.

[185]  A. George,et al.  Molecular mechanism for an inherited cardiac arrhythmia , 1995, Nature.

[186]  C. Foster,et al.  Differential expression of voltage‐activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro , 1995, FEBS letters.

[187]  M. Rousseau,et al.  Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease , 1994, Cardiovascular Drugs and Therapy.

[188]  W. Catterall,et al.  Molecular determinants of state-dependent block of Na+ channels by local anesthetics. , 1994, Science.

[189]  Suzuki Toru,et al.  The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[190]  S. Waxman,et al.  Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. , 1994, Journal of neurophysiology.

[191]  G. Rolly,et al.  Neuropathic pain in a cancer patient responding to subcutaneously administered lignocaine. , 1993, The Clinical journal of pain.

[192]  R Dubner,et al.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. , 1992, The New England journal of medicine.

[193]  D. Price,et al.  Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy , 1992, Brain Research.

[194]  Y. Mizuki,et al.  Effects of mianserin on negative symptoms in schizophrenia. , 1990, International clinical psychopharmacology.

[195]  J. Kastrup,et al.  The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy , 1990, Pain.

[196]  M. Janse,et al.  Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. , 1989, Physiological reviews.

[197]  W. Catterall,et al.  Inhibition of inactivation of single sodium channels by a site-directed antibody. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[198]  F. Conti,et al.  Structural parts involved in activation and inactivation of the sodium channel , 1989, Nature.

[199]  G. Leijon,et al.  Central post-stroke pain — a controlled trial of amitriptyline and carbamazepine , 1989, Pain.

[200]  H. Duff,et al.  Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels. , 1988, Molecular pharmacology.

[201]  P. Vassilev,et al.  Identification of an intracellular peptide segment involved in sodium channel inactivation. , 1988, Science.

[202]  R. Dubner,et al.  Amitriptyline, but not lorazepam, relieves postherpetic neuralgia , 1988, Neurology.

[203]  Reinhardt Rüdel,et al.  Membrane defects in paramyotonia congenita (eulenburg) , 1987, Muscle & nerve.

[204]  P. Grafe,et al.  Adynamia episodica hereditaria with myotonia: A non‐inactivating sodium current and the effect of extracellular pH , 1987, Muscle & nerve.

[205]  J. Kastrup,et al.  Dercum's disease (adiposis dolorosa). Treatment of the severe pain with intravenous lidocaine , 1987, Pain.

[206]  J. Kastrup,et al.  Intravenous lidocaine infusion — a new treatment of chronic painful diabetic neuropathy? , 1987, Pain.

[207]  E. Streib.  Successful treatment with tocainide of recessive generalized congenital myotonia , 1986, Annals of neurology.

[208]  D. Clifford,et al.  Pain in multiple sclerosis. , 1984, Archives of neurology.

[209]  E. Williams.  A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs , 1984 .

[210]  B. Covino,et al.  Analgesic responses to i.v. lignocaine. , 1982, British journal of anaesthesia.

[211]  H. Merskey,et al.  Amitriptyline versus placebo in post-herpetic neuralgia , 1981, PAIN.

[212]  P. G. Kostyuk,et al.  Ionic currents in the somatic membrane of rat dorsal root ganglion neurons—I. Sodium currents , 1981, Neuroscience.

[213]  J. Rothenberg,et al.  Fine-needle aspiration biopsy with CT guidance. , 1981, American family physician.

[214]  R. W. Turkington.  Depression Masquerading as Diabetic Neuropathy , 1980, JAMA.

[215]  W. Matthews,et al.  Paroxysmal symptoms in multiple sclerosis , 1975, Journal of the Neurological Sciences.

[216]  S. Blom.  Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). , 1962, Lancet.

[217]  A. Hodgkin,et al.  A quantitative description of membrane current and its application to conduction and excitation in nerve , 1952, The Journal of physiology.

[218]  J. Lemoyne.  [Use of dimethyl-dithio-hydantoin in treatment of certain facial neuralgias]. , 1950, Les Annales d'oto-laryngologie.

[219]  N. Bigelow,et al.  GENERAL ANALGESIC EFFECTS OF PROCAINE , 1944 .

[220]  M. Culpin.  Night-blindness: A Psychological Study , 1942 .

[221]  Ludovic C. Gillet,et al.  Beneficial effects of omega-3 long-chain fatty acids in breast cancer and cardiovascular diseases: voltage-gated sodium channels as a common feature? , 2011, Biochimie.

[222]  C. Argoff,et al.  Use of antiepileptic drugs for nonepileptic conditions: Psychiatric disorders and chronic pain , 2011, Neurotherapeutics.

[223]  Hugues Abriel,et al.  Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. , 2010, Journal of molecular and cellular cardiology.

[224]  R. Frau,et al.  Adjuvant activity of the novel sodium channel blocker NW-3509 in combination therapy with antipsychotics , 2010 .

[225]  H. Tan,et al.  UvA-DARE (Digital Academic Repository) Cardiac sodium channelopathies , 2010 .

[226]  K. A. Trujillo.  The neurobiology of opiate tolerance, dependence and sensitization: Mechanisms of NMDA receptor-dependent synaptic plasticity , 2009, Neurotoxicity Research.

[227]  M. Avoli,et al.  Lacosamide , 2009, CNS drugs.

[228]  O. Crociani,et al.  Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. , 2009, Current medicinal chemistry.

[229]  J. Krystal,et al.  Riluzole in the Treatment of Mood and Anxiety Disorders , 2008, CNS drugs.

[230]  Y. Gruel,et al.  Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines. , 2007, The international journal of biochemistry & cell biology.

[231]  W. Brackenbury,et al.  The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells , 2006, Breast Cancer Research and Treatment.

[232]  R. Kass,et al.  Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. , 2005, Trends in cardiovascular medicine.

[233]  S. Shorvon,et al.  The treatment of epilepsy , 2004 .

[234]  W. Löscher.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. , 2002, CNS drugs.

[235]  D. McCormick,et al.  On the cellular and network bases of epileptic seizures. , 2001, Annual review of physiology.

[236]  M. Boswell,et al.  Neuropathic pain: Review of mechanisms and pharmacologic management. , 2000, NeuroRehabilitation.

[237]  H. M. Bryson,et al.  Amitriptyline , 1996 .

[238]  H. Fozzard,et al.  The electrophysiology of acute myocardial ischemia. , 1985, Annual review of medicine.

[239]  R. Dengler,et al.  Effects of tocainide on normal and myotonic mammalian skeletal muscle. , 1979, Arzneimittel-Forschung.

[240]  C. Westerberg,et al.  Paroxysmal attacks in multiple sclerosis. , 1975, Brain : a journal of neurology.